Zenosense, Inc. (ZENO) Proceeds with Lung Cancer Detection Trial
Presently, only a small amount of lung cancer cases are spotted in the relatively treatable first stage of the disease – less than 20%. Now, what if a non-invasive, cost-effective early detection screening method were developed? It will likely offer noticeable improvements in survival rates and decreases in mortality rates. This is where Zenosense comes in. Zenosense, an emergent healthcare technology company, has taken on the challenge of developing functioning yet cost-effective medical devices that will detect, early on, deadly bacteria and certain cancers in a patient’s exhaled breath. One of the devices under development at the company is a…